AIA
RXRX icon

AssuredPartners Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

AssuredPartners Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123K Buy
33,546
+10,413
+45% +$34.7K 0.01% 408
2026
Q1 		$72.9K Buy
23,133
+2,538
+12% +$9.81K 0.01% 398
2025
Q4 		$84.2K Buy
+20,595
New +$102K 0.01% 338

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AssuredPartners Investment Advisors's RXRX Position: Q2 2026 in Review

AssuredPartners Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 45% in Q2 2026, buying an estimated $34.7K and bringing the position to 33,546 shares worth $123K. The position accounts for 0.01% of the portfolio, ranked #408.

AssuredPartners Investment Advisors first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • AssuredPartners Investment Advisors held 33,546 shares of Recursion Pharmaceuticals worth $123K as of Q2 2026.
  • AssuredPartners Investment Advisors bought 10,413 Recursion Pharmaceuticals shares in Q2 2026, an estimated $34.7K.
  • Recursion Pharmaceuticals made up 0.01% of AssuredPartners Investment Advisors's portfolio in Q2 2026, its #408 holding.
  • AssuredPartners Investment Advisors first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.